AYA ALL: Pediatric and Adult Inspired Regimens

EP: 1.Clinical Scenario: A 23-Year-Old Male with AYA ALL

EP: 2.AYA ALL: Overview and Risk Stratification

Now Viewing

EP: 3.AYA ALL: Pediatric and Adult Inspired Regimens

EP: 4.AYA ALL: Role of Asparaginase Erwinia Chrysanthemi

EP: 5.Asparaginase Erwinia Chrysanthemi: Side Effects and Hypersensitivity Reactions

EP: 6.ALL AYA: Coordination of Care

EP: 7.Clinical Scenario of a 32-Year-Old Female with AYA ALL and the Role of Cytogenetics in AYA ALL

EP: 8.CALBG 10403 in AYA ALL

EP: 9.The Potential of Modified Treatment Regimens in AYA ALL

EP: 10.The Future of AYA ALL

Video content above is prompted by the following questions:

• What is the current treatment landscape for AYA ALL?
  • How has the treatment landscape evolved over time?
• What is the role of asparaginase in the treatment of ALL in adolescents and young adults (AYA)?
  • What are some challenges in treating this patient population?
• When treating AYA ALL in your practice, do you usually consider a pediatric-inspired regimen or an adult-inspired regimen?
  • Have you noticed a difference in outcomes between pediatric and adult regimens?